Literature DB >> 16704293

TGN1412: time to change the paradigm for the testing of new pharmaceuticals.

Nirmala Bhogal1, Robert Combes.   

Abstract

Clinical studies in human volunteers are an essential part of drug development. These studies are designed to account for possible differences between the effects of pharmaceutical products in preclinical studies and in humans. However, the tragic outcome of the recent Phase 1 clinical trial on TGN1412 casts considerable doubt over the relevance of this traditional drug development paradigm to the testing of therapeutic agents for human use. The role of alternatives to animal testing is considered, and a series of recommendations are made, which could ensure that clinical trials are well informed and based on the most relevant scientific information.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16704293     DOI: 10.1177/026119290603400204

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  7 in total

Review 1.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

2.  Ethical issues in clinical trials involving nanomedicine.

Authors:  David B Resnik; Sally S Tinkle
Journal:  Contemp Clin Trials       Date:  2006-11-17       Impact factor: 2.226

3.  From pharmacology to immunopharmacology.

Authors:  Adam Cohen
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

Review 4.  Ethics in nanomedicine.

Authors:  David B Resnik; Sally S Tinkle
Journal:  Nanomedicine (Lond)       Date:  2007-06       Impact factor: 5.307

5.  Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.

Authors:  Zvi Teitelbaum; Thierry Lave; Jan Freijer; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

6.  Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations.

Authors:  Jarrod Bailey; Michael Balls
Journal:  BMC Med Ethics       Date:  2019-03-01       Impact factor: 2.652

Review 7.  The use of integrated and intelligent testing strategies in the prediction of toxic hazard and in risk assessment.

Authors:  Michael Balls; Robert D Combes; Nirmala Bhogal
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.